We are now in the third year of the Covid-19 pandemic. It is likely that Covid and the virus that causes...

There has been a great deal of buzz around nasal vaccines over the past two years. The idea is simple...

Three years into the Covid-19 pandemic, it is clear that some of us produce stronger immune reactions...

This article is part of a larger series on the risks of molnupiravir. For a summary of the risks at the...

One of the major time hindrances to the development of monoclonal antibodies is one of the first steps:...

A new ACE2 decoy mechanism efficiently neutralizes a variety of Covid-19 variants, including Omicron...

The current generation of monoclonal antibodies are ineffective against the predominant variants of SARS-CoV-2...

Entering the fourth year of Covid-19, vaccination has become the frontline of protective measures to...

This article is an extension of our series on immune suppression by SARS-CoV-2. The series has since...

The treatment of severe Covid-19 has proven difficult over the past three years, illustrated most clearly...